Acnetrait

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acnetrait

Acnetrait is a powerful prescription-only medication primarily used to treat severe, persistent skin conditions, and it is formally classified as a systemic anti-acne agent. It is defined by its ability to act internally throughout the body to modify underlying skin processes, distinguishing it fundamentally from treatments that are applied only to the skin's surface. Isotretinoin (the active ingredient in Acnetrait) is clinically recognized by dermatological guidelines as one of the most effective oral treatments for nodular, recalcitrant acne.


Quick Facts

Property Description
Active ingredient Isotretinoin (13-cis-retinoic acid)
Form Oral soft gelatin capsules
Pharmacological class Retinoid (Vitamin A derivative)
Route of administration Oral (for systemic absorption)
Origin Synthetic

What Type of Medicine is Acnetrait?

Acnetrait belongs to the retinoid pharmacological class, a category of compounds structurally and functionally related to Vitamin A (retinol). The active pharmaceutical ingredient is Isotretinoin, chemically known as 13-cis-retinoic acid.

Isotretinoin is a synthetic retinoid, meaning it is manufactured to mimic the action of natural Vitamin A metabolites. This classification confirms that Acnetrait works by mimicking essential biological signaling pathways related to skin cell growth. This oral medication is reserved for patients with severe nodular lesions that have not responded adequately to conventional antibiotics or topical therapies, relying on a potent, body-wide mechanism of action.


What is the Composition and Form?

Acnetrait is a single-ingredient product supplied as oral capsules, typically formulated as soft gelatin capsules. The capsules contain only Isotretinoin as the active substance. Because Isotretinoin is highly lipophilic (fat-soluble), it is compounded within a lipid base (such as an oil vehicle) inside the capsule; this specialized composition is necessary to ensure the medication is efficiently absorbed into the bloodstream from the gastrointestinal tract and delivered systemically.

Isotretinoin acts by profoundly suppressing sebaceous gland function. This action indicates that the drug's fundamental benefit comes from its powerful ability to reduce skin oil.


What is the General Purpose of This Systemic Agent?

The general therapeutic purpose of Acnetrait is to fundamentally correct the physiological abnormalities that drive the formation of severe acne lesions. This medicine achieves its goal by acting on two key areas: first, it drastically reduces the size of the sebaceous glands to minimize sebum (oil) production, and second, it normalizes keratinization (skin cell turnover) to prevent pores from becoming blocked. By addressing these foundational issues internally, Acnetrait aims to resolve persistent conditions that originate beneath the skin's surface, offering a unique systemic approach that is recognized in medical practice.

Regulatory References

  1. U.S. National Library of Medicine
  2. NIH: MedlinePlus

What side effects are possible with Acnetrait?

Possible Side Effects and Safety Information

Acnetrait (Isotretinoin) is a potent systemic retinoid with an officially documented safety profile characterized by systemic and dose-related adverse reactions. The most critical regulatory safety constraint is the profound risk of teratogenicity (severe birth defects); the drug is an absolute contraindication in pregnancy and for women of childbearing potential not adhering to an official risk management program.

Documented Adverse Reaction Categories

Adverse reactions are classified by frequency and often revert to baseline upon discontinuation. The effects are typically grouped by affected body system, consistent with regulatory standards.

Classification Examples of Officially Documented Effects
Very Common (>1 in 10) Cheilitis (lip inflammation), dry skin, dry eyes, arthralgia (joint pain), back pain, and elevated liver enzymes (transaminases).
Uncommon / Rare Depression, mood alteration, psychotic symptoms, and suicidal ideation are documented safety concerns.

Serious Systemic Considerations

Official labeling documents a range of serious, potentially irreversible systemic reactions. These include inflammatory bowel disease (such as regional ileitis), hepatitis, pseudotumor cerebri (benign intracranial hypertension), and severe cutaneous adverse reactions.

Acnetrait is also formally contraindicated in patients with severe hepatic impairment, uncontrolled hyperlipidaemia, and in those taking tetracyclines or other Vitamin A preparations, due to the risk of combined toxicity.

Overdose and Emergency Response

Overdose Scope

Element Regulatory Statement
Documented Overdose Presentations Acute signs of overdose are consistent with features of hypervitaminosis A. Officially documented symptoms include vomiting, facial flushing, headache, dizziness, ataxia (loss of coordination), cheilosis (chapped lips), and abdominal pain.
Physiological Systems Affected Effects are primarily documented across the Gastrointestinal and Central Nervous Systems. The most critical outcome is fetal toxicity.
Dose-Related Factors The most serious documented outcome is the risk of severe, life-threatening birth defects following fetal exposure at any dosage. Acute, non-teratogenic symptoms in humans are documented to quickly resolve without residual effects.
Population-Specific Overdose Notes Patients who can become pregnant require immediate evaluation for pregnancy and specialized counseling due to the fetal risk. All patients must be restricted from donating blood for at least one month following the overdose.
Emergency-Response Statements Seek immediate medical attention for any suspected overdose. Immediate evaluation for pregnancy is required for female patients of childbearing potential. Treatment is described as symptomatic and supportive, as no specific antidote is known.
When Immediate Medical Help is Required Urgent medical attention is required immediately upon suspicion of overdose to manage acute symptoms and initiate mandated post-exposure procedures, specifically the pregnancy evaluation and required post-overdose monitoring.

Overdose Classifications (High-Level)

Element Regulatory Statement
Severity Classification The most severe potential outcome is classified as teratogenicity (life-threatening birth defects).
Overdose-Context Constraints No specific antidote is known. Treatment is symptomatic and supportive.

Resulting Overdose Structure

Official regulatory documents define the overdose profile primarily through two lens: the nature of acute, resolving symptoms (such as vomiting and headache) and the single, non-resolving severe outcome of teratogenicity. This structure mandates that emergency actions—contacting medical help and receiving an immediate pregnancy evaluation—are critical, not only for managing acute physical symptoms but primarily for initiating the documented regulatory protocols for fetal risk mitigation and post-overdose monitoring for patients of childbearing potential.

Therapeutic Uses of Acnetrait

Managing Symptoms of Severe, Persistent Acne

Acnetrait is a highly relevant medication applied in clinical settings that involve acute or unstable symptom patterns, such as severe recalcitrant nodular acne. This condition is characterized by periods of heightened symptoms, including large, deep, painful nodules and cysts, as well as other active blemishes (pimples, blackheads, and whiteheads). These symptoms are targeted when patients have not responded adequately to prior conventional symptomatic management, and the medication is indicated specifically for this severe form of acne.

This supportive therapeutic assistance contributes to easing the overall symptom load and helps to minimize the potential for long-term physical consequences, such as permanent scarring and disfigurement associated with these lesions. The medication is applied in scenarios where additional management of discomfort is required. This ultimately assists with maintaining functional stability and contributes to improving day-to-day comfort.


Support for severe acne symptoms helps improve day-to-day comfort during symptomatic periods.


Quick Fact: Support for Severe Blemishes


Eligibility and Restrictions for Use

Eligibility and Contraindications

Acnetrait (isotretinoin) use is governed by strict regulatory eligibility rules due to the extremely high risk of severe birth defects (teratogenicity).


Absolute Non-Eligibility

Population/Condition Eligibility Status
Pregnancy Absolutely Contraindicated (Category X)
Breastfeeding Contraindicated/Not Recommended
Hepatic Insufficiency Contraindicated
Excessively high blood lipids Contraindicated
Hypersensitivity to the drug or excipients Contraindicated

Restricted or Conditional Eligibility

Female patients of childbearing potential are eligible only if they fully comply with a mandatory regulatory Pregnancy Prevention Program (PPP) or REMS. This compliance includes confirming a negative pregnancy test and using two methods of effective contraception before, during, and for one month after treatment.

Use is approved for patients 12 years of age and older. Use in patients under 12 years of age is not established. Patients with conditions such as kidney disease, diabetes, or a history of psychiatric disorders require careful assessment and monitoring by a healthcare provider for continued eligibility.

What should I know about interactions with other medicines?

The official interaction profile for Acnetrait (isotretinoin) documents specific medicinal product and substance combinations that carry risks of pharmacokinetic or pharmacodynamic interactions, which are classified as follows:

Contraindicated Combinations

Classification Interacting Substance Official Interaction Outcome
Contraindicated Tetracycline Antibiotics Co-administration must be avoided due to the officially documented risk of developing intracranial hypertension (pseudotumor cerebri).

Additive Toxic and Pharmacodynamic Effects

  • Vitamin A Supplements Co-administration with supplements containing Vitamin A must be avoided due to the risk of additive toxic effects from high systemic retinoid load.
  • Bone-Affecting Agents Caution should be exercised when used with medicines known to cause bone loss, such as Phenytoin and Systemic Corticosteroids, due to concerns about potential interactive effects.

Contraception and Substance Interference

  • Progestin-Only Oral Contraceptives Regulatory documents classify this type of oral contraceptive as an unacceptable form of contraception because its effectiveness may be compromised during Acnetrait therapy.
  • St. John's Wort The herbal product Hypericum perforatum is officially cited as potentially interfering with the effectiveness of oral contraceptives, a critical interaction given the mandated pregnancy prevention requirements.

Exposure Modification

  • Food The absorption of oral isotretinoin is officially documented as being enhanced when administered with a high-fat meal, representing a pharmacokinetic interaction that significantly increases the body's exposure (Cmax and AUC) to the drug.

Mechanism of Action

Acnetrait functions primarily as a selective agonist for the Retinoic Acid Receptor (RAR) subtypes gamma and beta, but not alpha. This nuclear receptor family acts as a ligand-activated transcription factor. Upon binding to the receptor in the cell nucleus, Acnetrait forms a heterodimer complex with the Retinoid X Receptor (RXR). This complex subsequently binds to specific regulatory DNA sequences known as Retinoic Acid Response Elements (RAREs) located in the promoter regions of target genes.

The binding to RAREs modulates the transcription of specific genes involved in keratinocyte differentiation and proliferation. This pathway modulation results in the normalization of follicular epithelial growth within the pilosebaceous unit. Downstream, this action alters the cellular machinery in the sebaceous gland, leading to a decrease in the production and secretion of sebum by affecting the gene expression of key lipogenic enzymes. The system-level physiological consequence is a reduction in the abnormal hyperkeratinization and cellular adhesion that defines the initial formation of a microcomedo.

Dosage and Administration Information

How to Use Acnetrait (Isotretinoin) — Administration Guidelines

This information describes the drug's standard usage instructions.


Administration Scope

Component Instruction
Route Oral administration only.
Dosing Initial daily dose ranges from 0.5 to 1.0 mg/kg body weight. The maximum dose is typically 2.0 mg/kg/day for very severe or truncal disease.
Frequency The total daily dose is divided and taken twice daily (e.g., morning and evening).
Timing Standard capsules must be taken with a meal to ensure proper absorption. Some specific micronized formulations may be taken without regard to food, based on their individual label instructions.
Preparation Swallow the capsule whole with a liquid. Do not chew, crush, or open the capsule.

Course and Procedural Rules

Component Instruction
Course Duration A single course of therapy typically lasts 15 to 20 weeks.
Missed Dose If a dose is missed, skip that dose and resume the regular schedule with the next dose; do not take extra capsules to make up for a missed dose.
Age Restriction Approved for use in patients 12 years of age and older.
Restrictions The medicine is dispensed only through a restricted distribution program (e.g., iPLEDGE REMS). Prescriptions are limited to a 30-day supply and must be picked up within a mandated timeframe. Avoid donating blood during treatment and for 1 month after the last dose.

These administration guidelines describe the dosage, timing, and procedural requirements for using Acnetrait, ensuring standardized use.

Recent Clinical Evidence

Evidence for Use in Severe Recalcitrant Nodular Acne

Research for Acnetrait was studied for conditions characterized by fluctuating or episodic manifestations such as severe recalcitrant nodular acne. This research examined its use primarily through Randomized Controlled Trials (RCTs) and Systematic Reviews. Some RCTs also explored comparative outcomes against other active regimens or placebo. These studies were evaluated in populations of adolescents and adults who had persistent symptoms despite receiving conventional systemic and topical therapies.

Research examined several outcomes related to outcomes linked to inflammatory or irritative states; this included total lesion counts and overall acne severity. Findings describe patterns observed in the studies over defined, short-term intervals.

Evaluation of Primary Outcomes

The core focus of initial trials was observed in measurements of systemic or functional imbalance, specifically the assessment of sebum production. Researchers also examined how outcomes related to physical discomfort were observed over the defined study timeframes. Data suggest patterns related to sebum levels observed during the treatment period. Studies also describe patterns related to symptoms in the observed populations, specifically focusing on the number of inflammatory and nodular lesions.

Long-Term Studies and Durability of Response

Studies explored the course of the condition after a treatment cycle was completed, often involving observational settings and retrospective database analyses. The main focus was observed in the frequency of acne relapse—or recurrence—after the studied treatment ended. Long-term effects are not fully established by controlled trials. The evidence about sustained outcomes is limited, requiring reliance on less-controlled, long-term studies.

Research in Specific Patient Groups

Acnetrait was evaluated in specific populations, primarily adolescents aged 12 and older, and those who had already demonstrated treatment resistance to other established methods. While data is available for adolescents, comparative evidence is lacking for certain other groups, such as older adults with acne. Research exploring short-term symptom changes in these populations is limited. Therefore, results apply only to the populations studied in the existing trials.

Understanding Research Limitations and Gaps

This summary highlights that the evidence quality varies across studies, and findings were mixed on certain specific outcome measures. Sample sizes were modest in some of the initial trials. A significant limitation is that long-term effects are not fully established, requiring reliance on less-controlled, observational cohorts. This means research contributes to the broader evidence landscape and helps contextualize how patients reported their experience, but it does not determine whether an individual will respond similarly.

Key Studies & References

  1. Label: ISOTRETINOIN capsule, liquid filled (FDA Approved Label)

Frequently Asked Questions (FAQ)

Common questions about Acnetrait (FAQ)


Q: What is the biggest difference between Acnetrait and topical acne creams?

Acnetrait is fundamentally a systemic retinoid, meaning it is taken orally and works internally throughout the body. Official regulatory documents specify that the medicine is indicated for severe recalcitrant nodular acne, distinguishing it from most topical creams which are applied only to the skin’s surface.


Q: How quickly can I expect to see results from Acnetrait?

Studies indicate that a typical course of treatment lasts for 15 to 20 weeks. While some people may see results earlier, improvement is generally gradual, and official information suggests that acne may temporarily worsen before it starts to clear up. If a second course is considered, official guidance advises that it is not initiated until at least eight weeks after the first is complete.


Q: Can taking Acnetrait cause extreme dryness on the lips and skin?

Yes, dry skin and cheilitis (inflammation and dryness of the lips) are reported as very common adverse reactions in official product labeling. Official warnings highlight that the drug strongly affects skin moisture balance, which is an expected, dose-related effect of the medication.


Q: What happens if I get pregnant while I'm still taking Acnetrait?

Acnetrait is absolutely contraindicated during pregnancy due to a severe risk of birth defects. If a patient becomes pregnant, regulatory guidance advises immediate discontinuation of the medication. The patient should then be referred to a healthcare provider specializing in teratology (the study of birth defects) for counseling and evaluation.


Q: Is sun exposure completely forbidden while taking Acnetrait?

While sun exposure is not strictly forbidden, official patient information warns that the skin will be much more sensitive to the sun (photosensitive), especially at the start of treatment. Official product information advises patients to avoid overexposure to sunlight and to use a high-SPF sunscreen to prevent severe sunburn.


Q: What kind of moisturizers are safe to use while on Acnetrait?

Due to the dryness associated with this medication, patient guidance often recommends using a fragrance-free moisturizer regularly. Patient guidance suggests avoiding excessive washing of affected skin areas to help minimize irritation.


Q: Is Acnetrait ever prescribed for conditions other than acne?

The product is indicated only for the treatment of severe recalcitrant nodular acne in patients 12 years of age and older. This means its use is officially approved for this condition alone, and it is reserved for patients who have not responded adequately to other standard treatments.


Q: Are the side effects of Acnetrait permanent after stopping the medication?

Most common side effects, such as dry skin, typically resolve once the medication is stopped. However, official labeling notes that some adverse reactions, including dry eyes or a decrease in night vision, have been reported to persist in rare cases after treatment cessation.


Q: Can men experience any specific side effects from taking Acnetrait?

Side effects generally affect all patients, but postmarketing reports have specifically noted adverse reactions related to the reproductive system in men. These have included sexual dysfunction and decreased libido.


Q: Is it safe to get tattoos or piercings while undergoing Acnetrait therapy?

Regulatory warnings advise against aggressive procedures like dermabrasion for several months after finishing treatment due to the risk of abnormal scarring. While tattoos and piercings are not explicitly mentioned, procedures that affect skin healing may require caution.


Q: Can Acnetrait help with body acne as well as facial acne?

Yes, official dosing information confirms that the medicine is used for both facial and body acne. The labeling specifically mentions its use for patients whose disease is primarily manifested on the trunk (body).


Q: Do people typically need more than one course of Acnetrait in their lifetime?

A single course of therapy often leads to long-lasting remission for many patients. However, if acne does return, the regulatory guidance states that a second course should not be started until at least eight weeks after completing the first course, allowing time to assess the full treatment effect.


Q: Is it common for acne to return after stopping Acnetrait?

While a single course often produces prolonged remission, clinical studies indicate that some individuals may experience a recurrence of acne (relapse). Studies suggest the need for retreatment is possible in a percentage of patients.


Q: What should I do if my skin becomes extremely sensitive while on Acnetrait?

Skin irritation can occur, particularly when treatment begins. If severe irritation occurs, official patient information suggests contacting a healthcare provider. In some cases, a temporary dosage reduction may be necessary to manage the skin's reaction.


Q: Does Acnetrait affect vision or night vision?

Yes, official regulatory documents state that this medicine can cause decreased night vision, which has been reported to persist in rare cases after stopping the drug. It may also cause dry eyes, which can lead to contact lens intolerance.


Q: Can taking Acnetrait make me more prone to infections?

Official safety data has reported certain infections as possible adverse effects, including skin infections (like paronychial infections). Other infections, such as those affecting the upper respiratory tract, have also been noted in official reports.


Q: Is Acnetrait appropriate for adult-onset acne?

The medication is indicated for the treatment of severe acne in all patients 12 years of age and older, which includes adults. Eligibility is based on the severity and type of acne, not the patient's age of acne onset.


Q: Is it normal to feel joint or muscle aches while on Acnetrait?

Yes, muscle and joint pain (arthralgia) are listed as very common adverse reactions in the official product information. This effect is expected in some patients, though in most cases, these symptoms are reported to resolve after stopping the medication.


Q: Can I use chemical peels or lasers after I've finished my Acnetrait course?

Official documents caution against performing procedures like aggressive dermabrasion for several months after treatment ends. This is due to a risk of scarring, and similar caution is generally applied to other procedures that affect skin regeneration, such as chemical peels or lasers.


Q: Does Acnetrait affect the absorption of nutrients?

The drug’s interaction profile does note that isotretinoin may increase the absorption of oral calcium supplements. Comprehensive information on the absorption of other general nutrients is not widely specified in official regulatory documents.


Q: Is Acnetrait known to cause hair thinning or loss?

Yes, hair thinning has been reported as an adverse reaction in official safety data. In most cases, this is considered temporary, but reports have noted that hair thinning has persisted in rare instances after the medication is stopped.


Q: How does a doctor determine the correct initial dose of Acnetrait?

The starting dose is calculated based on the patient's body weight. The dose may be adjusted throughout the course of treatment based on how the individual's skin responds to the medicine and whether they experience clinical side effects.


Q: Is there any evidence that diet affects the success of Acnetrait treatment?

Official labeling emphasizes that the capsule must be taken with a meal to ensure proper absorption of the drug. Separately, patients with elevated blood lipids are sometimes advised to restrict their dietary fat intake.


Q: Can individuals with a history of certain allergies use Acnetrait?

Acnetrait is absolutely contraindicated for anyone with a known hypersensitivity to the drug or any of its inactive ingredients. Because some formulations use materials like soya oil, patients with allergies to peanut or soya are also typically advised not to use it.


Q: Why do some people refer to Acnetrait as a 'last resort' for acne?

This description is linked to the drug's official indication. Regulatory documents state that the medicine is reserved for patients whose severe nodular acne is recalcitrant, meaning it has not responded to other conventional therapies.


Q: Is there a maximum cumulative dose of Acnetrait a person should take?

Yes, European and other regulatory information suggests that a specific cumulative dose per treatment course is associated with increased remission rates and better long-term outcomes for patients.


Q: Does Acnetrait affect the menstrual cycle in women?

Postmarketing safety reports have noted adverse reactions related to the reproductive system, which include abnormal menses (menstrual periods) in women.


Q: How long does Acnetrait stay in your system after the last dose?

Regulatory requirements dictate that patients must avoid donating blood and women must use effective contraception for one full month after the last dose. This period is specified because of the drug's systemic presence and risk during this time.


Q: What is the purpose of the initial follow-up appointment after starting Acnetrait?

Initial follow-up appointments are required for monitoring purposes. This typically involves repeated testing of blood lipids (triglycerides) and liver enzymes to check for adverse effects, and monthly pregnancy tests for patients who can become pregnant.


Q: Can I use makeup or cosmetic products freely while on Acnetrait?

Patient guidance recommends minimizing the use of make-up and cosmetics. Where used, the use of non-comedogenic (less likely to block pores) or water-based products is often advised to prevent further irritation or blockage.


Q: Are there any alternative treatment options if Acnetrait side effects are too severe?

Acnetrait is generally reserved for use only after other treatments have proven ineffective for severe acne. These prior options, which may serve as alternatives, include topical retinoid creams, benzoyl peroxide, or oral antibiotics.

How should Acnetrait be stored and disposed of?

How to Store and Dispose of Acnetrait?

Acnetrait (isotretinoin) capsules must be stored under specific regulatory constraints to maintain product stability and ensure safe handling.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature between 20 C and 25 C (68 F to 77 F).
Protection Keep the capsules protected from light and from freezing.
Container Store in a closed container, preferably the original packaging.
Child Safety Keep this and all medications out of the reach of children.

Disposal Instructions

Official regulations require that unused or expired Acnetrait capsules not be thrown away in household waste or flushed down the toilet. Due to its potential risk to the environment, it is mandatory to return the unused product to a pharmacist or designated collection point for safe disposal in accordance with local, regional, and national pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acnetrait found in:

A-Z Index: